No 711

1-[2-[[(diphenylmethylene)imino]oxy]ethyl]-1,2,5,6-tetrahydro-3-pyridinecarboxylic acid hydrochloride (NO-711) (Sigma, St. Louis, MO, USA) was dissolved in normal saline and administered to mice i.p. at a volume of 10 ml/kg body mass.
Two treatment regimens were used to treat paclitaxel-treated mice; the first was a preventative/prophylactic treatment (Fig. 1A) and the second a therapeutic treatment (Fig. 1B). The doses of NO-711 were chosen based on those previously shown to have antinociceptive activity in mice (Kubo et al., 2009 (link)).
For the preventative treatment NO-711 3 mg/kg was co-administered daily with paclitaxel, as described above, for five consecutive days (Fig. 1A). The mice were assessed for the development of thermal hyperalgesia and cold allodynia on day 7 and those that received paclitaxel plus NO-711 were compared with the mice treated with the paclitaxel plus vehicle (for NO-711) only.
For the therapeutic treatment, NO-711 at doses of 1 mg/kg and 3 mg/kg, was administered once at seven days after first administration of paclitaxel (Fig. 1B), when mice had developed thermal hyperalgesia, as previously described (Parvathy & Masocha, 2013 (link)), and cold allodynia.
For the rotarod test NO-711 was administered once at doses of 3 mg/kg and 5 mg/kg to naïve mice.

Bicuculline (0131, Tocris), CGP 52432 (SML‐0593, Sigma), D‐AP5 (0106, Tocris), GABAzine/SR‐95531 (S106, Sigma), gaboxadol (T101, Sigma), NBQX (N171, Sigma), NO‐711 (N142, Sigma), Picrotoxin (P1675, Sigma), SNAP (0598, Tocris), THIP (T101, Sigma), TTX (1069/1, Tocris) and zinc chloride (Z0152, Sigma).